European CHMP recommends approval of baricitinib for the treatment of moderate to severe atopic dermatitis in adults

Baricitinib is currently approved in the EU to treat moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Final approval is awaited.


European Medicines Agency